Evaluating the Effect of Fumaria Parviflora L. in Uremic Pruritus

Evaluation the Effect of Fumaria Parviflora L. on Uremic Pruritus of End-stage Renal Disease Patients: A Randomized Double- Blind Placebo-controlled Clinical Trial

The purpose of this study is to determine whether Fumaria Parviflora L. can minimize severity of pruritus in patients with end-stage renal disease.

Uremic Pruritus is still a common complication in end-stage renal disease patients. The pathogenesis of Uremic Pruritus is unknown, therefore treatments are ineffective. According to several studies Uremic Pruritus is not an isolated skin disease. It seems to be a systemic inflammatory disease with a deranged balance of T helper cell differentiation. In this study investigators considered to evaluate effect of Fumaria Parviflora L. in uremic pruritus by a double blind placebo control clinical trial. It is hypothesized that oral Fumaria Parviflora L. may minimize uremic pruritus by decreasing serum Interferon gamma (IFN-γ) and high-sensitive C reactive protein (hs-CRP).

Inclusion Criteria:

• Hemodialysis patients
• Suffering from pruritus for at least 6 weeks
• Have not responded to other drugs
• visual analogue scale (VAS) equal or more than 4

Exclusion Criteria:

• Liver disease
• Respiratory disease
• Dermatological disease
• Hemoglobin less than 10
• Cholestasis
• Malignancies